Marizyme, Inc. – OTC:MRZM
Marizyme stock price today
$0.008
-0.00
-1.22%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Marizyme stock price monthly change
-77.14%
month
Marizyme stock price quarterly change
-77.14%
quarter
Marizyme stock price yearly change
-94.67%
year
Marizyme key metrics
Market Cap | 5.06M |
Enterprise value | 11.44M |
P/E | -0.24 |
EV/Sales | 38.76 |
EV/EBITDA | -0.24 |
Price/Sales | 27.58 |
Price/Book | 0.46 |
PEG ratio | N/A |
EPS | -1.38 |
Revenue | 549.69K |
EBITDA | -23.87M |
Income | -69.01M |
Revenue Q/Q | -74.52% |
Revenue Y/Y | 51.65% |
Profit margin | -17343.64% |
Oper. margin | -15532.51% |
Gross margin | 77.87% |
EBIT margin | -15532.51% |
EBITDA margin | -4342.49% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMarizyme stock price history
Marizyme stock forecast
Marizyme financial statements
| Jun 2023 | 184.73K | -20.57M | -11138.09% |
|---|---|---|---|
| Sep 2023 | 181.53K | -32.45M | -17875.49% |
| Dec 2023 | 150.56K | -9.76M | -6486.14% |
| Mar 2024 | 32.85K | -6.22M | -18950.82% |
| Jun 2023 | 36981452 | 29.71M | 80.34% |
|---|---|---|---|
| Sep 2023 | 36919841 | 58.86M | 159.45% |
| Dec 2023 | 22015075 | 26.67M | 121.17% |
| Mar 2024 | 21570043 | 32.40M | 150.22% |
| Jun 2023 | -1.19M | 0 | 1.07M |
|---|---|---|---|
| Sep 2023 | -1.15M | 0 | 1.42M |
| Dec 2023 | -1.25M | 0 | 930.52K |
| Mar 2024 | -849.69K | 0 | 707.37K |
Marizyme alternative data
| Aug 2023 | 13 |
|---|---|
| Sep 2023 | 13 |
| Oct 2023 | 13 |
| Nov 2023 | 13 |
| Dec 2023 | 13 |
| Jan 2024 | 13 |
| Feb 2024 | 13 |
| Mar 2024 | 13 |
| Apr 2024 | 13 |
| May 2024 | 13 |
| Jun 2024 | 13 |
| Jul 2024 | 13 |
Marizyme other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 106327 | 0 |
| Jul 2023 | 97000 | 0 |
| Aug 2023 | 105000 | 0 |
| Insider | Compensation |
|---|---|
Dr. Catherine J. Pachuk Ph.D. (1957) Executive Vice President & Chief Scientific Officer | $546,870 |
Tuesday, 16 April 2024 | ||
| Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ | globenewswire.com | |
Monday, 23 October 2023 | ||
| Marizyme CEO Delivers Business Update | globenewswire.com | |
Friday, 6 October 2023 | ||
| Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ | globenewswire.com | |
Friday, 18 February 2022 | ||
| U.S. IPO Weekly Recap: The IPO Market's Micro-Cap Run Continues With 2 Small Healthcare Deals | Seeking Alpha |
-
What's the price of Marizyme stock today?
One share of Marizyme stock can currently be purchased for approximately $0.01.
-
When is Marizyme's next earnings date?
Unfortunately, Marizyme's (MRZM) next earnings date is currently unknown.
-
Does Marizyme pay dividends?
No, Marizyme does not pay dividends.
-
How much money does Marizyme make?
Marizyme has a market capitalization of 5.06M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 176.6% to 645.81K US dollars.
-
What is Marizyme's stock symbol?
Marizyme, Inc. is traded on the OTC under the ticker symbol "MRZM".
-
What is Marizyme's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Marizyme?
Shares of Marizyme can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Marizyme's key executives?
Marizyme's management team includes the following people:
- Dr. Catherine J. Pachuk Ph.D. Executive Vice President & Chief Scientific Officer(age: 68, pay: $546,870)
-
How many employees does Marizyme have?
As Jul 2024, Marizyme employs 13 workers.
-
When Marizyme went public?
Marizyme, Inc. is publicly traded company for more then 12 years since IPO on 21 May 2013.
-
What is Marizyme's official website?
The official website for Marizyme is marizyme.com.
-
Where are Marizyme's headquarters?
Marizyme is headquartered at 109 Ambersweet Way, Davenport, FL.
-
How can i contact Marizyme?
Marizyme's mailing address is 109 Ambersweet Way, Davenport, FL and company can be reached via phone at +7 327237395.
Marizyme company profile:
Marizyme, Inc.
marizyme.comExchange:
OTC
Full time employees:
11
Industry:
Biotechnology
Sector:
Healthcare
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.
109 Ambersweet Way
Davenport, FL 33458
Davenport, FL 33458
CIK: 0001413754
ISIN: US5703721028
CUSIP: 570372102
